Shopping Cart 0
Cart Subtotal
USD 0

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Sodium And Chloride Dependent Glycine Transporter 1-Pipeline Review, H2 2018'; Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Sodium- and chloride-dependent glycine transporter 1 is a protein encoded by the SLC6A9 gene. It terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. It plays a role in regulation of glycine levels in NMDA receptor-mediated neurotransmission.

The report 'Sodium And Chloride Dependent Glycine Transporter 1-Pipeline Review, H2 2018' outlays comprehensive information on the Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Hematological Disorders and Metabolic Disorders which include indications Cognitive Impairment Associated With Schizophrenia (CIAS), Schizophrenia, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Cognitive Impairment, Memory Impairment, Parkinson's Disease, Pervasive Developmental Disorder (PDD) and Thalassemia.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)

- The report reviews Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics and enlists all their major and minor projects

- The report assesses Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Overview

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Companies Involved in Therapeutics Development

Boehringer Ingelheim GmbH

F. Hoffmann-La Roche Ltd

Pfizer Inc

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Drug Profiles

BI-425809-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bitopertin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNS-006-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-03463275-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGW-5-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GlyT1 for Parkinson's Disease and Schizophrenia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0410120-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Dormant Products

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Discontinued Products

Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Product Development Milestones

Featured News & Press Releases

Jan 21, 2014: Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia

Dec 06, 2010: Phase II Study with First-In-Class Investigational Drug Demonstrates Improvement In Negative Symptoms In Patients With Schizophrenia

Dec 06, 2010: Roche Announces Eight-Week Results From Phase II Study Of RG16781 In Patients With Schizophrenia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Molecule Type, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Boehringer Ingelheim GmbH, H2 2018

Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Pipeline by Pfizer Inc, H2 2018

Dormant Products, H2 2018

Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Therapeutic Products under Development, Key Players in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Therapeutics, Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Pipeline Overview, Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Pipeline, Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Pipeline Assessment


Companies

Boehringer Ingelheim GmbH

F. Hoffmann-La Roche Ltd

Pfizer Inc

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Pipeline Review, H2 2018

Summary

According to the recently published report 'Sodium And Chloride Dependent Glycine Transporter 1-Pipeline Review, H2 2018'; Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Sodium- and chloride-dependent glycine transporter 1 is a protein encoded by the SLC6A9 gene. It terminates the action of glycine by its high affinity sodium-dependent reuptake into presynaptic terminals. It plays a role in regulation of glycine levels in NMDA receptor-mediated neurotransmission.

The report 'Sodium And Chloride Dependent Glycine Transporter 1-Pipeline Review, H2 2018' outlays comprehensive information on the Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 3 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Central Nervous System, Hematological Disorders and Metabolic Disorders which include indications Cognitive Impairment Associated With Schizophrenia (CIAS), Schizophrenia, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Cognitive Impairment, Memory Impairment, Parkinson's Disease, Pervasive Developmental Disorder (PDD) and Thalassemia.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)

- The report reviews Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics and enlists all their major and minor projects

- The report assesses Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Overview

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Companies Involved in Therapeutics Development

Boehringer Ingelheim GmbH

F. Hoffmann-La Roche Ltd

Pfizer Inc

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Drug Profiles

BI-425809-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bitopertin-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DNS-006-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-03463275-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PGW-5-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GlyT1 for Parkinson's Disease and Schizophrenia-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0410120-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Dormant Products

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Discontinued Products

Sodium and Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9)-Product Development Milestones

Featured News & Press Releases

Jan 21, 2014: Roche provides update on the first two of six phase III studies of bitopertin in schizophrenia

Dec 06, 2010: Phase II Study with First-In-Class Investigational Drug Demonstrates Improvement In Negative Symptoms In Patients With Schizophrenia

Dec 06, 2010: Roche Announces Eight-Week Results From Phase II Study Of RG16781 In Patients With Schizophrenia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Molecule Type, H2 2018


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indication, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Boehringer Ingelheim GmbH, H2 2018

Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Pipeline by Pfizer Inc, H2 2018

Dormant Products, H2 2018

Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Therapeutic Products under Development, Key Players in Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Therapeutics, Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Pipeline Overview, Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Pipeline, Sodium And Chloride Dependent Glycine Transporter 1 (Glyt1 or Solute Carrier Family 6 Member 9 or SLC6A9) Pipeline Assessment


Companies

Boehringer Ingelheim GmbH

F. Hoffmann-La Roche Ltd

Pfizer Inc

chat_bubbleLet's Chat